Table 1. Baseline characteristics of all hepatocellular carcinoma patients.

Characteristic	Entire cohort, n (%)	Training cohort, n (%)	Test cohort, n (%)	P value
Total	372 (100.0)	186 (50.0)	186 (50.0)	–
Median follow-up days	556 (0–3,675)	555 (0–3,675)	563 (0–3,478)	0.99
Age	59.4±13.0	60.2±13.6	58.6±13.3	0.33
Gender				0.99
Male	253 (68.0)	126 (33.9)	127 (34.1)
Female	119 (32.0)	60 (16.1)	59 (15.9)
Tumor grade				0.88
I	55 (14.8)	25 (6.7)	30 (8.1)
II	176 (47.3)	92 (24.7)	84 (22.6)
III	124 (33.3)	62 (16.7)	62 (16.7)
IV	13 (3.5)	4 (1.1)	9 (2.4)
Unknown	4 (1.1)	3 (0.8)	1 (0.3)
Stage				0.89
I	172 (46.2)	80 (21.5)	92 (24.7)
II	86 (23.1)	47 (12.6)	39 (10.5)
III	85 (22.8)	42 (11.3)	43 (11.6)
IV	5 (1.3)	4 (1.1)	1 (0.3)
Unknown	24 (6.5)	13 (3.5)	11 (3.0)
T stage				0.52
I	182 (48.9)	82 (22.0)	100 (26.9)
II	94 (25.3)	51 (13.7)	43 (11.6)
III	79 (21.2)	43 (11.6)	36 (9.7)
IV	13 (3.5)	6 (1.6)	7 (1.9)
Unknown	4 (1.1)	4 (1.1)	0 (0.0)
N stage				0.94
Without metastasis	254 (68.3)	123 (33.1)	131 (35.2)
With metastasis	4 (1.1)	2 (0.5)	2 (0.5)
Unknown	114 (30.6)	61 (16.4)	53 (14.2)
M stage				0.37
Without metastasis	269 (72.3)	131 (35.2)	138 (37.1)
With metastasis	4 (1.1)	4 (1.1)	0 (0.0)
Unknown	99 (26.6)	51 (13.7)	48 (12.9)
Tumor status during follow-up				0.97
With tumor	112 (30.1)	58 (15.6)	54 (14.5)
Tumor free	233 (62.6)	116 (31.2)	117 (31.5)
Unknown	27 (7.3)	12 (3.2)	15 (4.0)
Vascular invasion				0.79
Micro	94 (25.3)	48 (12.9)	46 (12.4)
Macro	17 (4.6)	11 (3.0)	6 (1.6)
No	261 (70.2)	127 (34.1)	134 (36.0)
Family history of cancer				0.96
No	211 (56.7)	103 (27.7)	108 (29.0)
Yes	110 (29.6)	55 (14.8)	55 (14.8)
Unknown	51 (13.7)	28 (7.5)	23 (6.2)